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Illicit Opioid Use in Canada: Comparing Social, 
Health, and Drug Use Characteristics of 
Untreated Users in Five Cities (OPICAN Study) 
Benedikt Fischer, Jürgen Rehm, Suzanne Brissette, 
Serge Brochu, Julie Bruneau, Nady El-Guebaly, Lina Noël, 
Mark Tyndall, Cameron Wild, Phil Mun, and Dolly Baliunas 
ABSTRACT Most of the estimated 125,000 injection drug users (IDUs) in Canada use illicit
opioids and are outside treatment (i.e., methadone maintenance treatment). Empirical data
suggest that illicit opioid users outside treatment are characterized by various health and
social problem characteristics, including polydrug use, physical and mental morbidity,
social marginalization, and crime. Although required for evidence-based programming,
systematic information on this specific substance-user population is sparse in Canada to
date. This article presents and compares key characteristics of population of illicit opioid
users outside treatment in five cities across Canada (OPICAN cohort). Overall, the major-
ity of OPICAN participants regularly used both a variety of illicit opioids and cocaine or
crack, reported physical and mental health (e.g., mood disorder) problems, lacked perma-
nent housing, were involved in crime, and had their “ideal” treatment not available to
them. However, key local sample differences were shown, including patterns of heroin ver-
sus prescription opioid use and levels of additional cocaine versus crack use as well as indi-
cators of social marginalization. Illicit opioid user population across Canada differ on key
social, health, and drug use indicators that are crucial for interventions and are often dem-
onstrated between larger and smaller city sites. Differentiated interventions are required. 
KEYWORDS Canada, Comorbidity, Dependence, Health, Heroin use, Illicit opioid use,
Infectious disease, Methadone treatment, Polydrug use, Treatment. 
INTRODUCTION 
Canada is home to an estimated 80,000–125,000 injection drug users (IDUs), the
vast majority of which is estimated to use illicit opioids.1,2 Empirical information on
illicit opioid user populations in the Canadian context is sparse, although it is
highly important for policy and program development; available data are typically
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limited to data from the large cities and/or limited to treatment populations.3,6 A review
of the available patchwork of recent local illicit drug user populations in Canada
suggests that such populations consist predominantly of IDUs, who are character-
ized by multiple health, drug use, and social problems;3,7–10 however, such descrip-
tions also suggest major differences between these populations. For example, drug
overdose, infectious diseases such as human immunodeficiency syndrome (HIV) and
hepatitis C (HCV), and cocaine injection prevalence levels have been reported to be
more concentrated in the large urban centres, with Vancouver typically presenting
the highest levels.9–12 Little such indicator data have been available from other—
smaller—locations within Canada for systematic comparison and the development
of needs-based interventions as increasingly employed in other jurisdictions (e.g.,
Switzerland, Netherlands, Australia).13–16 
Worldwide, illicit drug use is a major contributor to the overall burden of dis-
ease; it is associated with increased mortality, morbidity, and disability. Morbidity
occurs primarily through infections and infectious diseases (i.e., HIV, HCV, HBV);
17 premature mortality is caused by overdose, suicide, HIV/AIDS, and end-stage
liver disease. It is estimated that injection drug use (IDU) alone is associated with
0.4% of deaths and 0.8% of disability adjusted life years worldwide.17,18 In Canada
as well as in many other countries, a substantive share of new HIV infections and
most of the new HCV infections are associated with IDU.19 International research
evidence suggests a substantive societal, morbidity, and mortality burden associated
with illicit opioid use and specifically among those users outside treatment.20,21
However, this evidence also points to an increasingly diversified and heterogeneous
picture of illicit opioid use populations, with implications for both intervention
needs and prospects. Specifically, illicit opioid users are at risk for drug overdose
death.22–25 Most illicit opioid users have injection histories, are infected with infec-
tious disease including HCV, or engage in risk behaviours for infectious disease (i.e,
HIV).26,27 Increasingly, noninjection modes of illicit opioid use are being reported in
different settings, resulting in lower levels of risk related to injection.28–30 Besides
infectious diseases, illicit opioid user populations typically have high prevalence of
psychiatric comorbidity as well as polydrug dependence.31–34 Many illicit opioid
users generate revenue for their considerable drug expenditures through criminal
activities and/or social support sources, thus also incurring major societal cost.35,36
A recent cost-of-illness analysis of a local sample of illicit opioid users in Toronto
found a social cost burden of $45,000 per untreated user/year.20 
In Canada and globally, methadone maintenance treatment (MMT) is cur-
rently the main treatment response for opioid dependence.21,37 MMT has been
shown to improve physical and mental health status, to reduce illicit drug use,
infectious disease risks, and crime involvement among those retained in treat-
ment.37–40 In Canada, the availability of MMT for individuals using heroin as well
as other forms of illicit opioids has substantially increased in the three large prov-
inces of British Columbia (BC), Ontario, and Quebec, specifically in their main
urban centres, in the past decade.41,42 Yet, MMT practices vary considerably (e.g.,
“high threshold” vs. “low threshold” or “maintenance” vs. “abstinence”
approaches) between and within these jurisdictions.43,44 Despite recent increases in
availability, the utilization of MMT is low in Canada overall compared with many
other Western countries; only about 25 to 30% of the estimated illicit opioid user
population are utilising MMT at any given time.21,45 Alternative opioid mainte-
nance treatments existing elsewhere—such as buprenorphine, or heroin prescription—
are not currently available as regular treatment options in Canada.21,46 
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Given the lack of comparable data on illicit opioid user populations in sites
across Canada and the essential importance of such information for needs and
evidence-based intervention planning, a multisite cohort study of untreated illicit
opioid users in the five cities of Vancouver, Edmonton, Toronto, Montreal, and
Quebec City (“OPICAN” study) was established. The principal objectives for this
study are (1) to assess the key characteristics and behaviours of untreated illicit opi-
oid use in different local settings across Canada and (2) to monitor these indicators
over time. The OPICAN study is an ongoing project component of a multiyear
“Interdisciplinary Health Research Team” focusing on “Illicit Opiate Addiction
Research, Treatment and Policy” (funded by the Canadian Institutes of Health
Research) CIHR; other interlinked project components include animal studies,
meta-analyses, and clinical feasibility studies, all targeted towards a final synthesis
of results with the aim of context-specific prevention and treatment development.47 
METHODS 
The OPICAN study is being conducted in the five study sites according to a uniform
study protocol. To be eligible for study entry, individuals must (1) use illicit opioids
on the majority of days per week and have done so for at least 1 year, (2) not have
been in a drug treatment program in the previous 6 months, and (3) be at least 18
years old. Study sites used snowball recruitment techniques (by way of flyers, posters,
community liaisons, and word-of-mouth); interested potential study participants
were screened for eligibility according to a standard screening protocol adminis-
tered in person or by telephone. Those persons deemed eligible were invited to the
local study office, where they provided informed consent for the study as well as
contact information for follow-up purposes. The study received ethical review
board approval in all participating local institutions; however, no approval was
given for the saliva antibody test component in Edmonton. 
All participants completed a saliva confirmation drug test for opioid use. We
ensured anonymity and confidentiality of the data collected and paid a subject fee
of CDNS 20. Each participant was given a unique study code and identifier for
follow-up and data processing purposes. For the baseline component, the following
subject assessment components were implemented: 
(1) Semistructured, interviewer-administered questionnaire on social, health,
drug use, crime, and treatment characteristics (open and closed-ended
items).
(2) Saliva immunoassay screen test for HIV antibodies (Biochem Detect v 1
screen test and Vironostika HIV1 Micro Elisa confirmation test) and HCV
antibodies (Ortho Diagnostic HCV 3.0 SAVe Elisa screen test and Bio-Rad
Monolisa anti-HCV Plus version2 confirmation test):48,49 sensitivity and
specificity values for tests for both virologic antibody strands are some-
what limited [HIV: depending on the population, collection, and testing
method used, sensitivity ranges from 97.2–100%, specificity ranges from
97.7–100%.50,51 HCV: sensitivity values for method used have been reported
at 81% (range: 72–88%), specificity at 98% (range: 89–100%);48,52 these
values were confirmed with a small saliva/blood serum confirmation sample
from 20 external subjects] and upward adjustment of cut-off value has
likely led to underreporting for HCV; however, the practical feasibility and
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acceptance benefits of the salivary testing methods with the specific research
population and setting compensated for these limitations. 
(3) Composite International Diagnostic Interview (CIDI)–Short Form (Depres-
sion) 53 
Baseline data reported in this article were collected between March and Decem-
ber, 2002. Six hundred seventy-nine participants were enrolled, with enrolment caps
for each site [Caps were N=200 for the larger cities (i.e., Montreal, Toronto and
Vancouver), and N=100 for the smaller cities (Edmonton and Quebec City)]. Data
from component 1 and 3 were locally entered into a standardized data entry shell
and then centrally cleaned and analysed; saliva antibody samples for component 2
were analysed at the Public Health Laboratory of the Ontario Ministry of Health
and Long-term Care. Results from component 2 were provided by study identifica-
tion code and entered into the central study database. Statistical analyses were
conducted using SPSS,54 using study site as the major independent variable. In testing
for differences between sites, the method used was based on the scaling level of the
variable under consideration: analyses of variance (ANOVA) for metric data,
Kruskal–Wallis and median tests where the assumptions of ANOVA failed, and
table analyses for categorical data. Statistical significance was defined at the 5%
level. For cross-tabulations resulting in an overall significant Pearson chi-square,
the highlighted differences between cities have a minimum adjusted standardized
residual of 2.0. 
The OPICAN cohort will be monitored in several follow-up waves, initially
until 2005. 
RESULTS 
Social, Economic, and Legal Characteristics 
Table 1 summarizes that, on average, cohort participants were in their mid-30s;
only the Montreal sample was slightly younger with a mean age of under 30 years.
Two thirds of the cohort sample were male. Most of the participants in the cohort
were white, although this proportion differed across sites; both Vancouver and
Edmonton had a substantial Aboriginal group of almost one third of the overall
sample in their respective subcohorts. More than half of the cohort did not have
permanent housing, but lived in transitional housing or on the street; greatest differ-
ences existed between Quebec City, where three quarters of participants were
permanently housed, and Vancouver, where three quarters of participants were not
permanently housed. 
The largest proportion of participants—about one quarter—with legal
income from paid work were found in Montreal and Toronto; Vancouver had the
smallest with about 6%. The main sources of income generation (by amounts gen-
erated) for the total cohort were semilegal activities (including panhandling, hustling,
and sex work), drug dealing, and government support payments (welfare, social
assistance, etc.). 
About half of the overall cohort on average were arrested in the previous year,
with just under 6 in 10 in Vancouver and just over 4 in 10 in Toronto. Most arrests
were for property offences, whereas arrests for drug offences played a relatively
minor role. A slightly smaller proportion of the overall cohort had been in detention
in the previous year, with subcohort extremes of just over half in Vancouver and
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just over one third in Montreal. In all sites except for Quebec City, the vast majority
of participants were under some form of criminal justice restraint (probation, criminal
record, parole, etc.). 
Drug Use and Injection Risks 
Table 2 summarizes that drug use patterns were rather diverse across the five local
cohort populations. In the previous 30 days, heroin was the most commonly used
opioid drug; it was used by a substantive majority in Vancouver and Montreal, by
about half of the participants in Toronto, but by only a minority of participants in
Edmonton and Quebec City. Of other opioids, hydromorphone use was most com-
mon in Quebec City, Edmonton, and Toronto, but only reported by a small minor-
ity in Vancouver and Montreal. Codeine substances were used by the majority in
Toronto and Edmonton, but least commonly in Vancouver and Montreal. The use
of street methadone was reported by almost one third in Toronto; use of “other”
prescription opioids (e.g., meperidine, morphine, oxycodone) was reported by vast
majorities in Toronto and Edmonton but by only small minorities in the other three
sites. 
For nonopioid drugs, most of the overall sample reported using cocaine and
crack, but the usage differed considerably across sites. Cocaine use was reported by
vast majorities of the local samples in Quebec City and Montreal, whereas crack
use was reported by majorities in Vancouver, Edmonton, and Toronto. Majorities
of participants in all sites reported combined use of opioid and nonopioid drugs
(e.g., “speedballs” consisting of heroin and cocaine combinations). 
Considerable variation across sites existed with respect to routes of drug
administration. The vast majority of cohort participants had a lifetime injection
history, yet the current prevalence of injecting drugs (i.e., in the previous 30 days)
ranged from less than two thirds of participants in Toronto to more than 9 out of
10 participants in Vancouver. 
A minority of subjects—with a range of less than 1 in 10 in Vancouver to more
than 2 in 10 in Montreal—reported the sharing of needles in the previous 30 days;
injection equipment was shared in the previous 30 days by about one quarter of the
overall cohort. Somewhat less than 1 in 5 participants across the cohort reported
experiencing a drug-related overdose in the previous 6 months. 
Health Status 
The best “personal health” status was indicated by the Montreal sample with a
“good or better” rating by almost 6 in 10, whereas the Toronto sample reported the
worst health status with a “fair or poor” rating also by almost 6 in 10 participants.
(Table 3) The most participants in Edmonton and Toronto and the least in Mont-
real and Quebec City stated that they had a physical health problem. Among those
citing health problems, hepatitis and pain were cited overall as the two single most
serious physical health problems, reported most frequently in Vancouver (hepatitis)
and Quebec City (pain). On the basis of the results of salivary testing, HIV antibody
positivity was greatest in Vancouver with over 1 in 5 participants; Vancouver (2 in
3 participants) and Quebec City (3 in 5) were the two sites indicating the majority
of cohort participants to be HCV antibody positive (Edmonton excluded from this
component of analysis). 
Mental health problems, in the form of mood disorders, were self-reported by
about two thirds of the cohort; anxiety disorders were self-reported by about 1 in
10 participants in the overall cohort. Standardized assessment for depression using
256
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the CIDI–SF instrument resulted in a positive screening result for most of the partic-
ipants in all sites except for Vancouver, where this was the case for only one third of
participants. 
Health and Social Service Utilization 
Health care services were being received by substantial majorities of participants in
Edmonton and Toronto, yet only by a minority in Montreal; the health care
received was rated “good or better” by two thirds or more in local samples. (Table 4)
In the previous 6 months, walk-in clinics were used most in Edmonton and
Vancouver and least in Quebec City and Toronto; emergency rooms were used by
about half the overall cohort; private physicians were used most in Toronto and
Quebec City and least in Montreal and Vancouver. Needle exchange services (fixed)
were accessed by clear majorities of participants in all sites except for Toronto. For
other social services, welfare offices were used most often in Vancouver and least in
Montreal and Quebec City; drop-in shelters were used by vast majorities of partici-
pants except for the Montreal and Quebec City sites, where only a minority propor-
tion utilized such facilities. 
Drug Treatment 
The greatest proportions of participants in Edmonton and Montreal, and the
smallest proportions of participants in Vancouver, Quebec City, and Toronto, had
involvement in any drug treatment program in the year prior to study entry. (Table 5)
Somewhat less than half of all participants with such a treatment history in the
overall cohort had been involved in MMT. Less than one third of the overall
cohort stated that they wanted to be in an MMT program. A minority of cohort
participants had tried or wanted to enter some form of drug treatment in the previ-
ous year but had been unable to access treatment. Clear sample majorities in Tor-
onto and Edmonton, yet only minorities in the other three sites, indicated that
there was an “ideal” form of treatment (meeting their self-perceived distinct treat-
ment needs or preferences) that they would be willing to enter and utilize if it were
available. 
DISCUSSION 
Our OPICAN study findings present a unique systematic comparison of key charac-
teristics and behaviours of illicit opioid users outside treatment in five urban study
locations across Canada. The most important finding, overall, is that the five local
opioid user samples assessed differ considerably on most key indicators evaluated in
this study; this underlines the great need for locally accentuated and needs-based
interventions. 
Concretely, our study presents a couple of important findings about differen-
tial drug use patterns: First, the use of illicit opioids in the OPICAN cohort is by
far not limited to heroin but includes a wide variety of prescription opioids
(including diverted methadone). In Edmonton and Quebec City, for example, the
primary opioid drugs used were, in fact, prescription opioids. This may be related
to the dynamics of local drug cultures, or illicit drug markets in smaller locales, in
which prescription opioids substitute for limited heroin supply. This observation
coincides with reports of extended diverted prescription opioid use in urban cen-
tres across North America and elsewhere,55–57 emphasising the need for further
investigation. 
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Secondly, illicit opioid use in our study cohort is intricately linked to regular
cocaine or crack use, or the use of opioid/cocaine combinations, although funda-
mental local differences again exist with regards to specific drug use profiles.31,58,59
In this context, again, a key question is whether these pattern differences are driven
by local market, drug culture, or individual preference dynamics, as they also entail
considerable differences for ensuing health (i.e., injections) risks and harms. The
documented varying polydrug use profiles also have major implications for the
nature of opioid treatment programs as currently offered (i.e., MMT), many of
which still exclude or penalise regular cocaine/crack users. 
It should be further highlighted that in specific sites (e.g., Toronto), a substan-
tial number of participants primarily use their opioid drugs by noninjection routes
of administration (i.e., oral and smoking). This mirrors recent observations in some
other jurisdictions60,61 and has major implications for prevention and treatment.
Further analyses will have to focus on the determinants and consequences (e.g.,
infectious disease status) of these behaviour patterns, and how these can be utilized
in intervention efforts.29,30,62 The OPICAN cohort, overall, presented high HCV and
HIV prevalence levels. In conjunction with these infectious disease indicators,
it should be of concern that many study participants still reported the sharing of
needles and, even more so, injection equipment.63 In times where needle exchange
services are broadly available in the study sites, the remaining barriers for such risk
reduction measures in the study population must be investigated and addressed.61,62 
Considering wider social determinants of drug use and health, our study docu-
ments that a majority of the OPICAN participants were not permanently housed,
drew substantively from semilegal or illegal income sources, and had criminal
justice system (including detention) exposure. Thus, they are characterized by con-
ditions of social marginalization as well as exposure to risk environments which
have been demonstrated widely to be associated with inferior health status or out-
comes.66–69 It is notable, however, that on a number of health status characteristics
assessed in our study, participants in the (province of) Quebec sites fared somewhat
better compared to the other sites. Further investigations will have to explain the
determinants and consequences of this difference on key risk and health outcomes,
especially in light of the fact that participants from the two Quebec sites also
reported overall levels of health and social care utilization, overall, compared to
other sites. 
Participants reported an overall high level of burden of both physical health
(infectious disease, pain, other) and mental health (depression) problems, confirm-
ing that “opioid dependence” predominantly occurs in connection with a multitude
of comorbidities and needs to be addressed as such.32,70–72 This situation is empha-
sized by the result that half of the cohort rated their health status to be “fair” or
“poor”, gauging their health status far below the Canadian general population,
among whom only 12% report such status.73 Importantly, a number of the comor-
bidities (e.g., depression) reported in the OPICAN sample have been shown to neg-
atively influence addiction treatment prospects or outcomes.74,75 At the same time,
drug dependency hinders many individuals from access to general health care or
receiving specialized care (e.g., HCV treatment).76,77 Further analysis also needs to
explore specifically to which extent the cooccurrence of opioid and cocaine/crack
use is associated with psychiatric comorbidity status (and thus may be driven by
potential dynamics of “self-medication”) among cohort participants,78 and to what
extent these specific polydrug use patterns and resulting intervention needs are not
met by existing treatment services. 
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Given the picture of OPICAN participants’ drug treatment histories as well as
the limited interest in existing treatment options, our study seems to confirm that
the currently existing opioid treatment landscape in Canada—consisting predomi-
nentaly of MMT—is vastly insufficient.21,45 Reasons for the very limited utilization
of existing treatment options may lie in the distinct needs of users as well as in the
current structures or practices of treatment programs.79 However, given the sub-
stantial social and health burden from illicit opioid use not effectively reached by
treatment as well as the desire expressed for more suitable (“ideal”) treatment by
many participants, a determined needs-based expansion of treatment options must
urgently occur. 
As one key limitation of the OPICAN study, it needs to be pointed out that
illicit opioid use is a typically hidden activity and occurs in locally and behav-
iourally dispersed subpopulations; the representativeness and generalisability of our
study results for the phenomenon of illicit opioid use in its entirety in the sites
examined, or for Canada as a whole, are thus limited. However, studies of
untreated drug user populations are important for complementing information
derived from treatment-population samples, which are often primarily relied on for
intervention planning. 
Overall, findings from the OPICAN study aim to facilitate the development of
locally specific and needs-based prevention and treatment interventions for illicit
opioid users; this is also the primary purpose of the Interdisciplinary Health
Research Team project’s (already initiated) knowledge synthesis component. An
improved prevention—including context and local population specific “harm
reduction” measures—and treatment landscape for illicit opiate users in Canada is
urgently required. 
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